SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma.
作者信息
Sgherza Nicola, Curci Paola, Rizzi Rita, Attolico Immacolata, Loconsole Daniela, Mestice Anna, Chironna Maria, Musto Pellegrino
机构信息
Hematology and Bone Marrow Transplantation Unit, AOUC Policlinico, Bari, Italy.
Department of Emergency and Organ Transplantation, "Aldo Moro" University School of Medicine, Bari, Italy.
出版信息
Blood Cancer J. 2021 Dec 14;11(12):201. doi: 10.1038/s41408-021-00597-y.
Abstract
摘要
相似文献
1
SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma.接种过疫苗的多发性骨髓瘤患者感染新型冠状病毒2型（SARS-CoV-2）的情况。
Blood Cancer J. 2021 Dec 14;11(12):201. doi: 10.1038/s41408-021-00597-y.
2
Attenuated humoral immune response following anti-SARS-CoV-2 vaccine in heavily pretreated patients with multiple myeloma and AL amyloidosis.在接受过大量治疗的多发性骨髓瘤和AL淀粉样变性患者中，抗SARS-CoV-2疫苗接种后体液免疫反应减弱。
Am J Hematol. 2021 Dec 1;96(12):E475-E478. doi: 10.1002/ajh.26373. Epub 2021 Oct 16.
3
Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma.多发性骨髓瘤患者对BNT162b2免疫接种的T细胞反应严重受损。
Blood. 2022 Jan 6;139(1):137-142. doi: 10.1182/blood.2021013429.
4
Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma.抗CD38疗法会损害多发性骨髓瘤患者针对新冠病毒α和δ变体的疫苗反应。
Blood. 2022 Feb 10;139(6):942-946. doi: 10.1182/blood.2021013714.
5
Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia.多发性骨髓瘤和华氏巨球蛋白血症无症状前驱期患者对SARS-CoV-2疫苗的反应减弱。
Cancer Cell. 2022 Jan 10;40(1):6-8. doi: 10.1016/j.ccell.2021.12.003. Epub 2021 Dec 9.
6
Kinetics of anti-SARS-CoV-2 neutralizing antibodies development after BNT162b2 vaccination in patients with amyloidosis and the impact of therapy.淀粉样变性患者接种BNT162b2疫苗后抗SARS-CoV-2中和抗体的产生动力学及治疗的影响
Am J Hematol. 2022 Jan 1;97(1):E27-E31. doi: 10.1002/ajh.26406. Epub 2021 Nov 23.
7
Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy.加强接种BNT162b2优化骨髓瘤患者的SARS-CoV-2体液反应：抗BCMA疗法的负面影响。
Blood. 2022 Mar 3;139(9):1409-1412. doi: 10.1182/blood.2021014989.
8
COVID-19 timeline of events.2019冠状病毒病事件时间表。
Nat Med. 2021 Dec;27(12):2054-2055. doi: 10.1038/s41591-021-01618-w.
9
Audio Interview: Waning Immunity against SARS-CoV-2.音频访谈：针对严重急性呼吸综合征冠状病毒2的免疫力下降
N Engl J Med. 2021 Dec 9;385(24):e99. doi: 10.1056/NEJMe2119211.
10
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose.骨髓瘤老年患者在接种第一剂BNT162b2疫苗后对新冠病毒的中和抗体反应较低。
Blood. 2021 Jul 1;137(26):3674-3676. doi: 10.1182/blood.2021011904.
引用本文的文献
1
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).《后疫情时代多发性骨髓瘤合并 COVID-19 患者的管理：来自欧洲骨髓瘤网络（EMN）的共识文件》。
Leukemia. 2023 Jun;37(6):1175-1185. doi: 10.1038/s41375-023-01920-1. Epub 2023 May 4.
2
Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis.多发性骨髓瘤患者的 SARS-CoV-2 疫苗免疫原性：系统评价和荟萃分析。
Blood Adv. 2022 Dec 27;6(24):6198-6207. doi: 10.1182/bloodadvances.2022008530.
本文引用的文献
1
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA.接种疫苗的血液系统恶性肿瘤成年患者中的 COVID-19：来自 EPICOVIDEHA 的初步结果。
Blood. 2022 Mar 10;139(10):1588-1592. doi: 10.1182/blood.2021014124.
2
Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients.造血干细胞移植患者接种BNT162b2抗SARS-CoV-2 mRNA疫苗后的血清学反应。
Br J Haematol. 2022 Feb;196(4):928-931. doi: 10.1111/bjh.17873. Epub 2021 Oct 18.
3
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA).COVID-19 感染成年血液病患者：欧洲血液学协会调查（EPICOVIDEHA）。
J Hematol Oncol. 2021 Oct 14;14(1):168. doi: 10.1186/s13045-021-01177-0.
4
Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations.血液肿瘤患者和接受 SARS-CoV-2 疫苗接种的医护人员的体液免疫反应。
JAMA Oncol. 2022 Jan 1;8(1):106-113. doi: 10.1001/jamaoncol.2021.5437.
5
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.在 COVID 症状研究应用程序的英国用户中，疫苗接种后 SARS-CoV-2 感染的风险因素和疾病特征：一项前瞻性、基于社区的、嵌套的病例对照研究。
Lancet Infect Dis. 2022 Jan;22(1):43-55. doi: 10.1016/S1473-3099(21)00460-6. Epub 2021 Sep 1.
6
Severe COVID-19 by SARS-CoV-2 Lineage B.1.1.7 in Vaccinated Solid-Organ Transplant Recipients: New Preventive Strategies Needed to Protect Immunocompromised Patients.接种疫苗的实体器官移植受者中由SARS-CoV-2谱系B.1.1.7引起的重症COVID-19：需要新的预防策略来保护免疫功能低下的患者。
Vaccines (Basel). 2021 Jul 21;9(8):806. doi: 10.3390/vaccines9080806.
7
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment.COVID-19 疫苗接种后骨髓瘤患者的中和抗体反应高度依赖于抗骨髓瘤治疗的类型。
Blood Cancer J. 2021 Aug 2;11(8):138. doi: 10.1038/s41408-021-00530-3.
8
Development of COVID-19 Infection in Transplant Recipients After SARS-CoV-2 Vaccination.接种SARS-CoV-2疫苗后移植受者中COVID-19感染的发展情况。
Transplantation. 2021 Sep 1;105(9):e104-e106. doi: 10.1097/TP.0000000000003836.
9
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution.第五周抗 SARS-CoV-2 BNT162b2 疫苗在接受积极治疗的多发性骨髓瘤和骨髓增生性恶性肿瘤患者中的免疫原性和安全性：来自单一机构的初步数据。
J Hematol Oncol. 2021 May 17;14(1):81. doi: 10.1186/s13045-021-01090-6.
10
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose.骨髓瘤老年患者在接种第一剂BNT162b2疫苗后对新冠病毒的中和抗体反应较低。
Blood. 2021 Jul 1;137(26):3674-3676. doi: 10.1182/blood.2021011904.
Zotero 插件